At its Sept. 14, 2026 interim results briefing, Junshi Biosciences said JS203 (CD20/CD3 bispecific) is expected to initiate Phase III trials in 2026. JS207 (PD-1/VEGF bispecific) is in Phase II and is being tested in combination with chemotherapy, monoclonal antibodies and ADCs across multiple tumor types; Junshi plans to start Phase III for JS207 in 2026.

2026-09-14

At its Sept. 14, 2026 interim results briefing, Junshi Biosciences said JS203 (CD20/CD3 bispecific) is expected to initiate Phase III trials in 2026. JS207 (PD-1/VEGF bispecific) is in Phase II and is being tested in combination with chemotherapy, monoclonal antibodies and ADCs across multiple tumor types; Junshi plans to start Phase III for JS207 in 2026.